- Home
- CAPL vs PHAT Comparison
CAPL vs PHAT Comparison
Compare CAPL & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPL
- PHAT
- Stock Information
- Founded
- CAPL 1992
- PHAT 2018
- Country
- CAPL United States
- PHAT United States
- Employees
- CAPL N/A
- PHAT N/A
- Industry
- CAPL Oil Refining/Marketing
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- CAPL Energy
- PHAT Health Care
- Exchange
- CAPL Nasdaq
- PHAT Nasdaq
- Market Cap
- CAPL 793.6M
- PHAT 820.8M
- IPO Year
- CAPL 2012
- PHAT 2019
- Fundamental
- Price
- CAPL $20.62
- PHAT $11.97
- Analyst Decision
- CAPL
- PHAT Strong Buy
- Analyst Count
- CAPL 0
- PHAT 5
- Target Price
- CAPL N/A
- PHAT $16.40
- AVG Volume (30 Days)
- CAPL 24.1K
- PHAT 1.1M
- Earning Date
- CAPL 11-05-2025
- PHAT 11-06-2025
- Dividend Yield
- CAPL 10.23%
- PHAT N/A
- EPS Growth
- CAPL 100.77
- PHAT N/A
- EPS
- CAPL 1.13
- PHAT N/A
- Revenue
- CAPL $3,522,840,000.00
- PHAT $114,039,000.00
- Revenue This Year
- CAPL N/A
- PHAT $207.52
- Revenue Next Year
- CAPL N/A
- PHAT $96.46
- P/E Ratio
- CAPL $18.22
- PHAT N/A
- Revenue Growth
- CAPL N/A
- PHAT 1049.82
- 52 Week Low
- CAPL $19.50
- PHAT $2.21
- 52 Week High
- CAPL $25.73
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- CAPL 47.61
- PHAT 58.24
- Support Level
- CAPL $20.30
- PHAT $11.88
- Resistance Level
- CAPL $20.67
- PHAT $13.00
- Average True Range (ATR)
- CAPL 0.47
- PHAT 0.69
- MACD
- CAPL -0.01
- PHAT -0.09
- Stochastic Oscillator
- CAPL 37.67
- PHAT 41.14
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.